![]() And that was a strength which helped us along this way.” ![]() ![]() “As scientists we are used – particularly because we have always worked in technology innovation – we are used to solve problems and unknowns in real time. Türeci also spoke of how a “gender balanced team is one of the key success factors” in BioNTech’s work, boosting in particular the problem solving capabilities of the company. Blueprint clinical trials, whereby the company pre-discusses with regulators the switch in sequence, are also being deployed.Īlthough emerging variants are something BioNTech has to take “seriously,” Türeci told CNN that there is “no reason for fear currently.” The company uses its “fast and adaptable” mRNA platform to exchange the genetic sequence of the old variant against that of the new one, according to Türeci. Single Pfizer vaccine shot provides strong protection for those who've had Covid-19, UK studies suggest (Photo by Frank Augstein / POOL / AFP) (Photo by FRANK AUGSTEIN/POOL/AFP via Getty Images) Frank Augstein/Pool/AFP/Getty Images Britain on December 8 hailed a turning point in the fight against the coronavirus pandemic, as it begins the biggest vaccination programme in the country's history with a new Covid-19 jab. Resources are being directed into being “prepared for tomorrow in case such a variant of concern would occur: the processes with which we can adapt to a new variant,” Türeci added.Ī nurse administers the Pfizer-BioNTech COVID-19 vaccine at Guy's Hospital in London, on December 8, 2020. The company is also being kept busy by the continuous need to test the robustness of their vaccine against new variants of the virus.īased on their analysis, the current vaccine has been found to be effective against the variants first detected in the UK and South Africa, with Türeci stressing that the company’s priority is ascertaining “which variant is of real concern.” In an exclusive interview with CNN, BioNTech co-founder and chief medical officer Özlem Türeci said the company is “continuously reevaluating how the target we have already set could be even overperformed.”ĭespite certain limitations such as the fact that they “cannot train people very fast” the company is focusing on finding partners “who can complement pieces of this pretty large network” of vaccine supply. The makers of the Pfizer/BioNTech coronavirus vaccine are “turning every stone” to scale up production capacity as Europe continues to suffer from a deficit in vaccine supply.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |